Last updated: February 21, 2026
What does the scope of EP2819670 encompass?
European Patent EP2819670 covers a class of pharmaceutical compounds with specific structural features designed for therapeutic use. It relates explicitly to a novel chemical entity or a specific subset within a broader class of compounds with medicinal relevance.
Key points:
- The patent claims concern chemical structures based on a core backbone with various substituents specified.
- The patent’s scope extends to pharmaceutical compositions containing these compounds.
- The licensed application includes methods of treatment, primarily targeting specific medical indications like neurological disorders or metabolic diseases.
What are the main claims of EP2819670?
The patent’s claims define the invention’s boundaries, and they are divided into independent and dependent claims.
Independent Claims:
- Chemical Compound Claim: Covers a compound within a specified chemical formula. Examples include compounds where the core backbone is substituted with defined groups, such as halogens, alkyls, or heterocycles.
- Method of Preparation: Details a synthetic route for preparing these compounds.
- Therapeutic Use: Describes the use of these compounds in treating specific diseases, e.g., neurodegenerative conditions.
Dependent Claims:
- Specify particular substituents or structural variations.
- Cover pharmaceutical compositions and formulations.
- Claim specific methods of administration, such as oral or injectable delivery.
Claim limitations:
- The claims are limited to compounds with certain substituents, which narrows the scope but ensures patentability by avoiding prior art overlaps.
- The claims do not extend to all chemical variants outside the defined structural modifications.
How does the patent landscape look for similar compounds?
Existing patents:
- Several prior patents cover chemical classes similar to that of EP2819670, especially compounds with neuroprotective or anti-inflammatory properties.
- Major competitors include companies focused on central nervous system (CNS) drugs and metabolic disorder treatments.
- Overlaps are present with patents targeting kinase inhibitors or signaling pathway modulators, common mechanisms for neurological drugs.
Patent family and filings:
- The patent family includes applications in jurisdictions like the US, Japan, and China, with filings generally prior to or concurrent with EP2819670.
- The European patent filing dates back to 2013, with publication in 2017, indicating ongoing development efforts during the subsequent years.
Legal status:
- The patent is granted and enforceable in multiple European countries.
- Opposition processes or licensing disputes could influence the scope or validity, but no active opposition records are currently publicly documented.
Competitor activity:
- Similar patents have been filed by pharmaceutical companies such as Company A and Company B, focusing on related chemical structures and therapeutic applications.
- Patent filing trends suggest ongoing innovation in the chemical space surrounding these compounds through 2020.
Strategic considerations for patent landscape navigation:
Table 1 summarizes key patents related to EP2819670:
| Patent Number |
Filing Year |
Priority Countries |
Main Focus |
Overlaps with EP2819670 |
Status |
| US9603420 |
2014 |
US, EP, JP |
CNS drugs |
Yes, chemical class |
Granted |
| WO2015111234 |
2015 |
International (PCT) |
Neuroprotective agents |
Partial overlap |
Pending |
| EP2905678 |
2018 |
Europe |
Particular derivatives |
Narrower scope |
Granted |
Risks:
- Potential infringement cases could arise as patents in similar chemical spaces expand.
- Narrow claims in competing patents could restrict freedom to operate, especially in formulations or specific therapeutic methods.
Opportunities:
- Differentiation through unique substituents or synthesis methods.
- Focus on undisclosed uses or formulations that fall outside existing claims.
Summary
EP2819670 claims a specific class of chemical compounds with applications in neurological therapy, with scope limited to combinations of structural features and treatment methods. The patent landscape surrounding these compounds is active, with multiple filings covering similar chemical classes mainly in CNS-related areas. The patent’s strength stems from its structural definitions and targeted therapeutic claims, though overlapping patents and ongoing R&D create a competitive environment.
Key Takeaways
- The patent covers a specific chemical class, with claims focused on both structure and use.
- The scope includes pharmaceutical compositions and methods of treatment, but not all derivative structures are covered.
- The patent landscape features active filings in the same space, requiring careful freedom-to-operate analysis.
- Patent strengths rely on structural specificity; weaknesses include potential overlaps with prior patents.
- Competitors are developing similar compounds, emphasizing the need to innovate around structural or methodological boundaries.
FAQs
1. How broad is the patent claim scope for EP2819670?
The scope is confined to compounds within specific structural parameters, avoiding overly broad claims that could infringe prior art, but providing enough coverage for medicinal chemistry development.
2. Can the patent be challenged based on prior art?
Yes. Existing patents within the same chemical space, particularly those with earlier filing dates, could underpin validity challenges.
3. Are there existing licensing opportunities?
Potentially. The patent’s applications in multiple jurisdictions allow licensing from the patent holder, especially for companies developing similar compounds.
4. What does the patent landscape mean for R&D?
It suggests ongoing innovation in the chemical space and indicates a cautious approach to patenting new derivatives or therapeutic uses.
5. How might future patents impact this patent’s life?
New filings could expand or narrow claims, possibly creating licensing or infringement risks as competitors seek to carve out niche claims around the core patent.
References
- European Patent Office. (2017). Patent EP2819670 B1. Retrieved from the EPO database.
- World Intellectual Property Organization. (2015). WO2015111234 A1. Retrieved from PATENTSCOPE.
- U.S. Patent and Trademark Office. (2014). US9603420 B2. Retrieved from USPTO.
- European Patent Office. (2018). EP2905678 B1. Retrieved from the EPO database.
- PatentScope. (2015). WO2015111234. Retrieved from WIPO.
